Ubs Group Ag Gracell Biotechnologies Inc. Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.43 - $10.04 $299,786 - $1.24 Million	123,369 Added 5336.03%	125,681 $1.26 Million
Q3 2023 Nov 09, 2023	SELL	$2.83 - $4.9 $1,199 - $2,077	-424 Reduced 15.5%	2,312 $6,000
Q2 2023 Aug 11, 2023	BUY	$1.45 - $6.07 $245 - $1,025	169 Added 6.58%	2,736 $10,000
Q1 2023 May 12, 2023	SELL	$1.8 - $2.5 $1,854 - $2,575	-1,030 Reduced 28.63%	2,567 $4,000
Q4 2022 Feb 08, 2023	SELL	$2.08 - $3.96 $636 - $1,211	-306 Reduced 7.84%	3,597 $8,000

Q3 2022 Nov 10, 2022	BUY	$2.08 - $5.15 $8,118 - $20,100	3,903 New	3,903 $13,000
Q1 2022 May 16, 2022	SELL	$1.83 - $5.52 $2,992 - $9,025	-1,635 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.65 - $14.9 $9,237 - $24,361	1,635 New	1,635 $10,000
Q3 2021 Nov 15, 2021	SELL	$9.91 - $14.84 $4,182 - $6,262	-422 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.75 - $18.42 $4,114 - $7,773	422 New	422 $5,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.